High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis

Heather A. Wroblewski, Richard Kovacs, Joanna R. Kingery, Brian R. Overholser, James E. Tisdale

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cardiac toxicity may be associated with drugs used for malaria. Torsades de pointes (TdP) is a well-known adverse effect of quinidine when used for atrial fibrillation. Intravenous quinidine doses for resistant malaria are 2 to 3 times higher than those used for arrhythmias. Among 6 patients receiving quinidine for malaria or babesiosis, 4 developed QT interval prolongation and 2 experienced TdP. Clinicians should be aware that recommended doses of quinidine for malaria carry a high TdP risk.

Original languageEnglish
Pages (from-to)4495-4499
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Babesiosis
Torsades de Pointes
Quinidine
Malaria
Therapeutics
Atrial Fibrillation
Cardiac Arrhythmias
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis. / Wroblewski, Heather A.; Kovacs, Richard; Kingery, Joanna R.; Overholser, Brian R.; Tisdale, James E.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 8, 08.2012, p. 4495-4499.

Research output: Contribution to journalArticle

@article{fa9a2fab4735484eb0f190043981b67c,
title = "High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis",
abstract = "Cardiac toxicity may be associated with drugs used for malaria. Torsades de pointes (TdP) is a well-known adverse effect of quinidine when used for atrial fibrillation. Intravenous quinidine doses for resistant malaria are 2 to 3 times higher than those used for arrhythmias. Among 6 patients receiving quinidine for malaria or babesiosis, 4 developed QT interval prolongation and 2 experienced TdP. Clinicians should be aware that recommended doses of quinidine for malaria carry a high TdP risk.",
author = "Wroblewski, {Heather A.} and Richard Kovacs and Kingery, {Joanna R.} and Overholser, {Brian R.} and Tisdale, {James E.}",
year = "2012",
month = "8",
doi = "10.1128/AAC.06396-11",
language = "English",
volume = "56",
pages = "4495--4499",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis

AU - Wroblewski, Heather A.

AU - Kovacs, Richard

AU - Kingery, Joanna R.

AU - Overholser, Brian R.

AU - Tisdale, James E.

PY - 2012/8

Y1 - 2012/8

N2 - Cardiac toxicity may be associated with drugs used for malaria. Torsades de pointes (TdP) is a well-known adverse effect of quinidine when used for atrial fibrillation. Intravenous quinidine doses for resistant malaria are 2 to 3 times higher than those used for arrhythmias. Among 6 patients receiving quinidine for malaria or babesiosis, 4 developed QT interval prolongation and 2 experienced TdP. Clinicians should be aware that recommended doses of quinidine for malaria carry a high TdP risk.

AB - Cardiac toxicity may be associated with drugs used for malaria. Torsades de pointes (TdP) is a well-known adverse effect of quinidine when used for atrial fibrillation. Intravenous quinidine doses for resistant malaria are 2 to 3 times higher than those used for arrhythmias. Among 6 patients receiving quinidine for malaria or babesiosis, 4 developed QT interval prolongation and 2 experienced TdP. Clinicians should be aware that recommended doses of quinidine for malaria carry a high TdP risk.

UR - http://www.scopus.com/inward/record.url?scp=84864386781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864386781&partnerID=8YFLogxK

U2 - 10.1128/AAC.06396-11

DO - 10.1128/AAC.06396-11

M3 - Article

C2 - 22615288

AN - SCOPUS:84864386781

VL - 56

SP - 4495

EP - 4499

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -